Sanofi starts Phase III clinical trial for efpeglenatide exported from Hanmi Pharm
A Phase III clinical trial for ‘efpeglenatide’ developed by Hanmi Pharm on its own and whose technology was transferred to Sanofi, a global pharmaceutical company, will start on 4 December.
On the 28th(local Korea time), ClinicalTrials, a global clinical trial information website, updated conten...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
